FR09C0048I2 - - Google Patents
Info
- Publication number
- FR09C0048I2 FR09C0048I2 FR09C0048C FR09C0048C FR09C0048I2 FR 09C0048 I2 FR09C0048 I2 FR 09C0048I2 FR 09C0048 C FR09C0048 C FR 09C0048C FR 09C0048 C FR09C0048 C FR 09C0048C FR 09C0048 I2 FR09C0048 I2 FR 09C0048I2
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63397496A | 1996-04-19 | 1996-04-19 | |
| US08/833,271 US5998402A (en) | 1996-04-19 | 1997-04-04 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR09C0048I1 FR09C0048I1 (enExample) | 2009-06-11 |
| FR09C0048I2 true FR09C0048I2 (enExample) | 2010-06-11 |
Family
ID=27092026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR09C0048C Active FR09C0048I2 (enExample) | 1996-04-19 | 2009-09-30 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0802183B1 (enExample) |
| JP (1) | JP4093611B2 (enExample) |
| KR (1) | KR100480193B1 (enExample) |
| CN (1) | CN1106383C (enExample) |
| AR (1) | AR011503A1 (enExample) |
| AT (1) | ATE206701T1 (enExample) |
| AU (1) | AU710149B2 (enExample) |
| BR (1) | BRPI9715334B8 (enExample) |
| CO (1) | CO4900051A1 (enExample) |
| CY (2) | CY2325B1 (enExample) |
| CZ (1) | CZ291701B6 (enExample) |
| DE (2) | DE122009000061I1 (enExample) |
| DK (1) | DK0802183T3 (enExample) |
| EA (1) | EA001448B1 (enExample) |
| ES (1) | ES2162198T3 (enExample) |
| FR (1) | FR09C0048I2 (enExample) |
| HU (1) | HU227077B1 (enExample) |
| IL (1) | IL120701A (enExample) |
| LU (1) | LU91608I2 (enExample) |
| MX (1) | MX9702865A (enExample) |
| NL (1) | NL300416I2 (enExample) |
| NO (2) | NO309564B1 (enExample) |
| NZ (1) | NZ314601A (enExample) |
| PT (1) | PT802183E (enExample) |
| SK (1) | SK281737B6 (enExample) |
| UA (1) | UA48148C2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2287980A1 (en) * | 1997-04-30 | 1998-11-05 | Daniel Jon Sall | Antithrombotic agents |
| ES2210747T3 (es) | 1997-05-01 | 2004-07-01 | Eli Lilly And Company | Agentes antitromboticos. |
| ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| CN1173973C (zh) * | 1998-05-12 | 2004-11-03 | 惠氏公司 | 苯并咔唑和茚并吲哚衍生的雌激素药 |
| US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
| CN1309637A (zh) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | 包含2－苯基－吲哚化合物和雌激素制剂的组合物 |
| SK284666B6 (sk) * | 1998-05-15 | 2005-08-04 | Wyeth | Farmaceutický prostriedok obsahujúci indolové zlúčeniny a estrogény a jeho použitie |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| EP0997465B1 (en) * | 1998-10-30 | 2004-02-04 | Eli Lilly And Company | Azaindole derivatives and their use as antithrombotic agents |
| TWI220898B (en) * | 1999-03-04 | 2004-09-11 | Wyeth Corp | N-substituted indolines as estrogenic agents |
| US6358943B1 (en) | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
| US6380185B1 (en) | 1999-03-04 | 2002-04-30 | American Home Products Corporation | N-substituted benzoyl indoles as estrogenic agents |
| CN1342144A (zh) * | 1999-03-04 | 2002-03-27 | 美国家用产品公司 | 用作雌激素药物的n－取代的苯甲酰基吲哚类化合物 |
| ES2254215T3 (es) * | 1999-09-13 | 2006-06-16 | Wyeth | Glucopiranosidos conjugados de 2-(4-hidroxi-fenil)-1-(4-(2-amin-1-il-etoxi)-benzil)-1h-indol-5-oles. |
| US6380166B1 (en) | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| AU2991301A (en) * | 2000-01-28 | 2001-08-07 | Endorecherche Inc. | Selective estrogen receptor modulators in combination with estrogens |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| AU2001271784A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
| EP1990051A1 (en) | 2000-07-06 | 2008-11-12 | Wyeth | Combinations of SSRI and estrogenic agents |
| AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| US6509332B2 (en) | 2000-07-06 | 2003-01-21 | Wyeth | Methods of treating excessive intraocular pressure |
| AU2001271781A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| EP1656938A1 (en) | 2000-07-06 | 2006-05-17 | Wyeth | Combinations of SSRI and estrogenic agents |
| WO2002003988A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
| WO2002003991A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
| US20020016318A1 (en) * | 2000-07-06 | 2002-02-07 | American Home Products Corporation | Methods of treating breast disorders |
| AR030064A1 (es) * | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
| EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| WO2002094788A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
| US6962928B2 (en) | 2001-05-22 | 2005-11-08 | Eli Lilly And Company | Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis |
| CA2489098A1 (en) * | 2002-06-13 | 2003-12-24 | Wyeth | Bazedoxifene treatment regimens |
| CA2490580C (en) | 2002-07-22 | 2012-12-11 | Eli Lilly And Company | Selective estrogen receptor modulators containing a naphthalene group |
| AU2003292625B2 (en) | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| US7250440B2 (en) * | 2003-08-12 | 2007-07-31 | Wyeth | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents |
| PA8629101A1 (es) | 2004-04-07 | 2005-11-25 | Wyeth Corp | Polimorfo cristalino de acetato de bazedoxifeno |
| KR20070004815A (ko) | 2004-04-07 | 2007-01-09 | 와이어쓰 | 바제독시펜 아세테이트의 결정질 다형체 |
| AU2005233128A1 (en) | 2004-04-08 | 2005-10-27 | Wyeth | Bazedoxifene ascorbate as selective estrogen receptor modulator |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| CN101022802A (zh) | 2004-07-22 | 2007-08-22 | Ptc医疗公司 | 用于治疗丙型肝炎的噻吩并吡啶化合物 |
| EP1791826A2 (en) * | 2004-08-05 | 2007-06-06 | Wyeth | Crystalline polymorph of pipendoxifene hydrochloride monohydrate |
| JP5057983B2 (ja) | 2004-10-20 | 2012-10-24 | アンドルシェルシュ・インコーポレイテッド | 閉経後の女性における膣乾燥および性機能障害の予防および処置のための性ステロイド前駆体単独あるいは選択的エストロゲン受容体モジュレータならびに／またはエストロゲン類および／もしくは５型ｃＧＭＰホスホジエステラーゼ阻害剤の併用 |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| US20100087661A1 (en) * | 2007-02-12 | 2010-04-08 | Josef Jirman | Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole |
| US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
| CA2714494A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth Llc | Methods of preparing polymorphic form a of bazedoxifene acetate |
| HUE025471T2 (hu) | 2008-04-16 | 2016-03-29 | Karobio Ab | Új ösztrogén receptor ligandumok |
| US20120253038A1 (en) * | 2009-04-13 | 2012-10-04 | Sandoz Ag | Processes for the synthesis of bazedoxifene acetate and intermediates thereof |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| ITMI20091109A1 (it) * | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
| MX2012014579A (es) | 2010-06-16 | 2013-05-22 | Endorech Inc | Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos. |
| US7968732B1 (en) | 2010-09-07 | 2011-06-28 | Divi's Laboratories, Ltd. | Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole |
| WO2012037187A2 (en) | 2010-09-14 | 2012-03-22 | Dr. Reddy's Laboratories Ltd. | Preparation of crystalline bazedoxifene and its salts |
| US8569483B2 (en) | 2011-06-21 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of bazedoxifene acetate and intermediates thereof |
| CN102690225B (zh) * | 2012-04-11 | 2014-12-24 | 南京友杰医药科技有限公司 | 巴多昔芬的合成方法 |
| US9751835B2 (en) * | 2013-05-15 | 2017-09-05 | Indiana University Research And Technology Corporation | Processes and intermediates for preparing indole pharmaceuticals |
| US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| EP3834824B1 (en) | 2014-03-28 | 2025-10-22 | Duke University | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| US9845291B2 (en) * | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| KR20190110400A (ko) | 2018-03-20 | 2019-09-30 | 엠에프씨 주식회사 | 새로운 중간체를 이용한 바제독시펜의 제조방법 |
| IT201800006562A1 (it) * | 2018-06-21 | 2019-12-21 | Procedimento e intermedi utili per la preparazione di indoli | |
| IT201900001923A1 (it) | 2019-02-11 | 2020-08-11 | Erregierre Spa | Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato |
| US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU373941A3 (enExample) * | 1970-01-21 | 1973-03-12 | ||
| DE2557342A1 (de) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | Basisch substituierte indolderivate und verfahren zu ihrer herstellung |
| US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| DE3232968A1 (de) * | 1981-09-10 | 1983-06-09 | Degussa Ag, 6000 Frankfurt | Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung |
| CA1241660A (en) * | 1984-06-25 | 1988-09-06 | Yvan Guindon | Indole-2-alkanoic acids |
| GB8707051D0 (en) * | 1986-04-15 | 1987-04-29 | Ici America Inc | Heterocyclic carboxamides |
| DE3821148A1 (de) * | 1988-06-23 | 1989-12-28 | Erwin Von Dr Angerer | Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| GB9004301D0 (en) * | 1990-02-26 | 1990-04-18 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
| US5051442A (en) * | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
| EP0639567A1 (en) * | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
| EP0634169B1 (en) * | 1993-06-29 | 2000-01-05 | Takeda Chemical Industries, Ltd. | Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis |
| GB9326332D0 (en) * | 1993-12-23 | 1994-02-23 | Karo Bio | Indole derivatives |
| DE4426625A1 (de) * | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
1997
- 1997-04-15 ES ES97302576T patent/ES2162198T3/es not_active Expired - Lifetime
- 1997-04-15 DE DE122009000061C patent/DE122009000061I1/de active Pending
- 1997-04-15 PT PT97302576T patent/PT802183E/pt unknown
- 1997-04-15 AT AT97302576T patent/ATE206701T1/de active
- 1997-04-15 EP EP97302576A patent/EP0802183B1/en not_active Expired - Lifetime
- 1997-04-15 DE DE69707189T patent/DE69707189T2/de not_active Expired - Lifetime
- 1997-04-15 SK SK472-97A patent/SK281737B6/sk not_active IP Right Cessation
- 1997-04-15 NZ NZ314601A patent/NZ314601A/en not_active IP Right Cessation
- 1997-04-15 DK DK97302576T patent/DK0802183T3/da active
- 1997-04-17 UA UA97041833A patent/UA48148C2/uk unknown
- 1997-04-17 CZ CZ19971175A patent/CZ291701B6/cs not_active IP Right Cessation
- 1997-04-17 AU AU18920/97A patent/AU710149B2/en not_active Expired
- 1997-04-18 AR ARP970101580A patent/AR011503A1/es active IP Right Grant
- 1997-04-18 JP JP10156397A patent/JP4093611B2/ja not_active Expired - Lifetime
- 1997-04-18 CN CN97113496A patent/CN1106383C/zh not_active Expired - Lifetime
- 1997-04-18 EA EA199700044A patent/EA001448B1/ru not_active IP Right Cessation
- 1997-04-18 MX MX9702865A patent/MX9702865A/es unknown
- 1997-04-18 HU HU9700777A patent/HU227077B1/hu active Protection Beyond IP Right Term
- 1997-04-18 CO CO97020584A patent/CO4900051A1/es unknown
- 1997-04-18 KR KR1019970014894A patent/KR100480193B1/ko not_active Expired - Lifetime
- 1997-04-18 NO NO971815A patent/NO309564B1/no not_active IP Right Cessation
- 1997-04-18 IL IL12070197A patent/IL120701A/xx active Protection Beyond IP Right Term
- 1997-04-22 BR BRPI9715334A patent/BRPI9715334B8/pt not_active IP Right Cessation
-
2003
- 2003-04-08 CY CY0300038A patent/CY2325B1/xx unknown
-
2009
- 2009-09-23 LU LU91608C patent/LU91608I2/fr unknown
- 2009-09-28 NL NL300416C patent/NL300416I2/nl unknown
- 2009-09-30 CY CY2009016C patent/CY2009016I2/el unknown
- 2009-09-30 FR FR09C0048C patent/FR09C0048I2/fr active Active
- 2009-11-09 NO NO2009025C patent/NO2009025I2/no unknown